• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

    4/22/25 8:08:00 AM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email

    Report highlights efforts to enhance access and equity in women's health and invest in the future with science-based environmental targets, employee development and community engagement

    Hologic, Inc. (NASDAQ:HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its annual sustainability report with an emphasis on expanded environmental commitments and efforts to advance access and equity in women's health.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422781805/en/

    Hologic 2024 Sustainability Report

    Hologic 2024 Sustainability Report

    For almost four decades, Hologic has pushed the limits of what's possible to improve women's health, and in 2024 its technologies impacted more than 193 million lives worldwide.1 As a science-based company, it has a long-standing approach to operate sustainably and responsibly.

    "We firmly believe that our success as a company is fundamentally tied to our ability and commitment to help millions of women worldwide live healthier lives," said Hologic Chairman, President and CEO Stephen P. MacMillan. "This is our reason for being. For us, women's health is more than a business; it is our purpose: to enable healthier lives everywhere, every day."

    The newly launched report covers four areas of focus reflecting the issues that directly impact Hologic's stakeholders, communities and women around the world. Below are highlights from each area in 2024:

    Advancing Women's Access and Equity in Healthcare

    • Brought innovative healthcare technologies to women globally, including through FDA clearance for the Genius™ Digital Diagnostics System2 for cervical cancer screening, the launch of Genius AI® Detection 2.03 solution for breast cancer screening and the acquisition of Endomagnetics and Gynesonics.
    • Released the fourth Hologic Global Women's Health Index in partnership with Gallup, bringing international attention to critical women's health issues based on data reflecting 97% of the global adult population.
    • Raised awareness of health issues impacting millions of women via its strategic partnership with the Women's Tennis Association (WTA) and through efforts such as the #BustTheMyth breast cancer awareness campaign and the "Better Is Possible" campaign focused on abnormal uterine bleeding, which received 7.3 million views.
    • Collaborated with health equity organizations such as the Black Women's Health Imperative and the National Alliance for Hispanic Health to support women's screening, diagnostic treatment and outreach services in communities across the U.S.
    • Launched initiatives aimed at advancing medical education within the healthcare community, including a partnership with the American Association of Gynecologic Laparoscopists (AAGL) focused on hysteroscopy, and a new project with the UK Royal College of Obstetricians and Gynaecologists to integrate technologies like AI into obstetric and gynecologic surgery.
    • Supported patient-focused programs that improve access to quality healthcare, such as the Promise Fund of Florida and Neighborhood Healthcare near Hologic's campus in San Diego.

    Protecting the Environment

    • Committed to achieving a 50% reduction in emissions by 2030 and net zero by 2050, aligned with the Science Based Targets initiative.
    • Achieved a 10% emission reduction across Scopes 1, 2 and 34 since 2020 baseline.
    • Completed Scope 3 carbon emission assessment of the full value chain and demonstrated a 10% absolute reduction and 16% reduction in emission intensity from 2020 baseline.
    • Reduced water use at key operational sites by 20% since baseline through initiatives like the Cooling Tower Water Project in San Diego and rainwater capture efforts in Costa Rica and Belgium.
    • Diverted 65% of waste from landfills, with three Hologic sites at over 90% diversion rates.

    Supporting Our People and Communities

    • Ranked in the 97th percentile of employee engagement, and 98% of employees surveyed feel Hologic's mission makes their job important, based on an annual survey conducted by Gallup.
    • Continued commitment to pay equity by maintaining a zero gender net pay gap.
    • Supported patients, communities and students by engaging with nonprofit organizations like SewHope to bring Pap tests for cervical cancer screening to women in Guatemala, sponsoring events such as the Susan G. Komen More Than Pink Walk to combat breast cancer, and engaging with students interested in STEM careers.
    • Donated $1.8M in corporate grants to support local communities in 2024.

    Operating With Integrity

    • Expanded sustainability reporting transparency aligning to the Global Reporting Initiative (GRI), the Task Force on Climate-Related Financial Disclosures (TCFD) and the Sustainability Accounting Standards Board (SASB) voluntary reporting frameworks.
    • Unveiled the company's first Cybersecurity Operations Center (SOC), a strategic hub in Costa Rica aimed at monitoring, detecting and responding to cyber threats.
    • Reinforced commitment to maintaining the highest standards of compliance and quality, with 12 Hologic sites holding ISO 13485 certifications.
    • 34% of strategic and preferred suppliers committed to science-based environmental sustainability targets.

    To read the full sustainability report, please visit www.hologic.com/sustainability.

    About Hologic, Inc.

    Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.

    Forward-Looking Statements

    This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

    Hologic, The Science of Sure, Genius and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    References and Notes

    1. Lives impacted include assays, mammograms, surgical treatments and other Hologic procedures.

    2. FDA clearance followed CE Mark.

    3. Available in Europe, Australia, New Zealand and the United States.

    4. Scope 1: direct emissions; Scope 2: emissions from purchased energy; Scope 3: indirect emissions in the value chain.

    SOURCE: Hologic, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250422781805/en/

    Media Contact

    Bridget Perry

    Senior Director, Corporate Communications

    (+1) 508.263.8654

    [email protected]

    Investor Contact

    Michael Watts

    Corporate Vice President, Investor Relations

    (+1) 858.410.8514

    [email protected]

    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Breast & Skeletal Horvath Mark W. covered exercise/tax liability with 113 shares, decreasing direct ownership by 0.49% to 23,026 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    2/12/26 4:10:47 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Amendment: SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4/A - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 5:11:14 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SVP, Human Resources De Walt Diana covered exercise/tax liability with 4,416 shares, decreasing direct ownership by 37% to 7,603 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    2/3/26 4:19:26 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

    Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice Hologic, Inc. (NASDAQ:HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic's human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/ Screening for cervical cancer is critically important to women's health. In the United States, it is estimated that in 2026, approximatel

    2/4/26 8:15:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of bulky, multi-million dollar hardware is giving way to agile, software-defined diagnostics. As point-of-care tools accelerate toward a $70.92 billion market[2], hospitals are trading dedicated MRI suites for bedside intelligence that delivers hospital-grade precision on a portable device. This seismic shift is placing a massive premium on the

    1/16/26 11:56:00 AM ET
    $BFLY
    $GEHC
    $HOLX
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    SEC Filings

    View All

    SEC Form 8-K filed by Hologic Inc.

    8-K - HOLOGIC INC (0000859737) (Filer)

    2/6/26 8:00:17 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by Hologic Inc.

    10-Q - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:08:35 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form DEFA14A filed by Hologic Inc.

    DEFA14A - HOLOGIC INC (0000859737) (Filer)

    1/29/26 4:04:16 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics